Because many immune-based therapies are designed to accentuate the CD8+ T cell immune response and augment IFN-γ production in the tumor microenvironment, understanding this unique and paradoxical mechanism of immunoregulation is critical for the rational design of therapeutic strategies specific for lung cancer. The gene discussed is IFNG; the disease is lung carcinoma.